Skip to main content

Steatohepatitis clinical trials at UC Davis

8 research studies open to eligible people

Showing trials for
  • A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver (NAFL) or Nonalcoholic Steatohepatitis (NASH)

    open to eligible people ages 2 years and up

    TARGET-NASH is a longitudinal observational cohort study of patients being managed for NAFL or NASH in usual clinical practice. TARGET-NASH will create a research registry of patients with NAFL or NASH within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.

    Sacramento, California and other locations

  • A Research Study of Experimental EDP-305 in Subjects With Liver-biopsy Proven NASH

    open to eligible people ages 18-75

    A randomized, double-blind study to assess the safety and efficacy of EDP-305 in subjects with liver-biopsy proven Non-Alcoholic Steatohepatitis (NASH)

    Sacramento, California and other locations

  • A Study of Experimental HM15211 Treatment in NASH

    open to eligible people ages 18-70

    This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH

    San Diego, California and other locations

  • A study of Metabolism and Blood flow in Non-Alcoholic Fatty Liver Disease Using the EXPLORER PET/CT Medical Scanner

    open to eligible people ages 18 years and up

    Evaluation of Multi-Organ Metabolism and Perfusion in Non-Alcoholic Fatty Liver Disease (NAFLD) by Total Body Dynamic PET Scan on EXPLORER

    Sacramento, California

  • A Study of the Experimental Medicine Obeticholic Acid For Nonalcoholic Steatohepatitis (NASH) (accumulation of liver fat)

    open to eligible people ages 18 years and up

    The primary objective of this study is to evaluate whether obeticholic acid (OCA; INT-747) can lead to histological improvement in fibrosis with no worsening of NASH in adults with compensated cirrhosis due to NASH.

    Sacramento, California and other locations

  • A Study to Test the Effectiveness and Safety of Experimental VK2809 for Biopsy Proven Non-Alcoholic Steatohepatitis (NASH)

    open to eligible people ages 18-75

    The study includes 52 weeks, double-blind treatment period. Clinic visits will occur at Randomization and every four weeks from Week 4 through Week 52 and through End of Study period. The study includes a post-dosing study visit that will occur 4 weeks after the last dose of study drug. This visit represents the End-of-Study Visit (Week 56 Visit). Three hundred thirty-seven subjects will be enrolled into five treatment arms and there will be an equal distribution of males and females in each treatment arm. Subjects will be stratified by gender, fibrosis stage, and diabetes status.

    Sacramento, California and other locations

  • Do you have Fatty Liver or NASH? Participate in a study

    “We are evaluating a new investigational medicine for the treatment of NASH”

    open to eligible people ages 18-75

    The primary objectives of this study are to evaluate the effect of Elafibranor treatment compared to placebo on 1) histological improvement and 2) all-cause mortality and liver-related outcomes in patients with nonalcoholic steatohepatitis (NASH) and fibrosis.

    Sacramento, California and other locations

  • Non-Invasive Evaluation of Liver Steatosis, Inflammation and Fibrosis

    “Comparison of imaging techniques used to evaluate patients with liver disease”

    open to eligible people ages 18 years and up

    The goal of this study is to evaluate non-invasive imaging techniques for determining liver steatosis (fat), inflammation (abnormal tissue swelling), and fibrosis (abnormal tissue scarring).In addition, the study group will be using other test measures including personal demographics, laboratory blood test results, and imaging measurements to determine the severity of NAFLD (non-alcoholic fatty liver disease), NASH (non-alcoholic steatohepatitis), inflammation, and fibrosis.

    Sacramento, California